ReP USP - Resultado da busca

Artigo de periodico
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 (2024)
Santos, Yasmin Silva ; Gamon, Thaís Helena Martins ; Azevedo, Marcela Santiago Pacheco de ; Bielavsky, Mônica ; Darido, Maria Laura Goussain ; Oliveira, Danielle Bruna Leal de ; Souza, Edmarcia Elisa de ; Luvizotto, Maria Cecília Rui ; Ackerman, Hans Christian; Carvalho, Leonardo José de Moura ; Epiphanio, Sabrina ; Wrenger, Carsten ; Durigon, Edison Luiz ; Marinho, Claudio Romero Farias
Source: Frontiers in Pharmacology. Unidades: FCF, ICB, BIOTECNOLOGIA
Subjects: PARASITOLOGIA, MICROBIOLOGIA, COVID-19, INIBIDORES DE ENZIMAS, DOENÇAS RESPIRATÓRIAS, ANGIOTENSINA II, SISTEMA RENINA-ANGIOTENSINA, ANTIVIRAIS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Yasmin Silva et al. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19. Frontiers in Pharmacology, v. 15, 2024Tradução . . Disponível em: https://doi.org/10.3389/fphar.2024.1414406. Acesso em: 01 nov. 2024.
APA
Santos, Y. S., Gamon, T. H. M., Azevedo, M. S. P. de, Bielavsky, M., Darido, M. L. G., Oliveira, D. B. L. de, et al. (2024). Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19. Frontiers in Pharmacology, 15. doi:10.3389/fphar.2024.1414406
NLM
Santos YS, Gamon THM, Azevedo MSP de, Bielavsky M, Darido MLG, Oliveira DBL de, Souza EE de, Luvizotto MCR, Ackerman HC, Carvalho LJ de M, Epiphanio S, Wrenger C, Durigon EL, Marinho CRF. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 [Internet]. Frontiers in Pharmacology. 2024 ; 15[citado 2024 nov. 01 ] Available from: https://doi.org/10.3389/fphar.2024.1414406
Vancouver
Santos YS, Gamon THM, Azevedo MSP de, Bielavsky M, Darido MLG, Oliveira DBL de, Souza EE de, Luvizotto MCR, Ackerman HC, Carvalho LJ de M, Epiphanio S, Wrenger C, Durigon EL, Marinho CRF. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 [Internet]. Frontiers in Pharmacology. 2024 ; 15[citado 2024 nov. 01 ] Available from: https://doi.org/10.3389/fphar.2024.1414406
Artigo de periodico
Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics (2023)
Perez-Vargas, Jimena ; Shapira, Tirosh ; Olmstead, Andrea D ; Villanueva, Ivan ; Thompson, Connor A. H; Ennis, Siobhan ; Gao, Guang; Guzman, Joshua De; Williams, David E ; Wang, Meng; Chin, Aaleigha; Bautista-Sanchez, Diana ; Agafitei, Olga ; Levett, Paul; Xie, Xuping; Nuzzo, Genoveffa ; Freire, Vitor Fernandes ; Bulla, Jairo L Quintana ; Bernardi, Darlon Irineu ; Gubiani, Juliana Regina ; Suthiphasilp, Virayu; Raksat, Achara; Meesakul, Pornphimol ; Polbuppha, Isaraporn; Cheenpracha, Sarot ; Jaidee, Wuttichai ; Kanokmedhakul, Kwanjai; Yenjai, Chavi; Chaiyosang , Boonyanoot; Teles, Helder Lopes; Manzo, Emiliano; Fontana, Angelo ; Leduc, Richard; Boudreault, Pierre-Luc ; Berlinck, Roberto Gomes de Souza ; Laphookhieo, Surat; Kanokmedhakul, Somdej; Tietjen, Ian; Cherkasov, Artem; Krajden, Mel ; Nabi, Ivan Robert ; Niikura, Masahiro; Shi, Pei-Yong; Andersen, Raymond J; Jean, Francois
Source: Antiviral Research. Unidades: IQSC, ESALQ
Subjects: ANTIVIRAIS, COVID-19, PANDEMIAS, PRODUTOS NATURAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREZ-VARGAS, Jimena et al. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Research, v. 209, p. 1-13, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.antiviral.2022.105484. Acesso em: 01 nov. 2024.
APA
Perez-Vargas, J., Shapira, T., Olmstead, A. D., Villanueva, I., Thompson, C. A. H., Ennis, S., et al. (2023). Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Research, 209, 1-13. doi:10.1016/j.antiviral.2022.105484
NLM
Perez-Vargas J, Shapira T, Olmstead AD, Villanueva I, Thompson CAH, Ennis S, Gao G, Guzman JD, Williams DE, Wang M, Chin A, Bautista-Sanchez D, Agafitei O, Levett P, Xie X, Nuzzo G, Freire VF, Bulla JLQ, Bernardi DI, Gubiani JR, Suthiphasilp V, Raksat A, Meesakul P, Polbuppha I, Cheenpracha S, Jaidee W, Kanokmedhakul K, Yenjai C, Chaiyosang B, Teles HL, Manzo E, Fontana A, Leduc R, Boudreault P-L, Berlinck RG de S, Laphookhieo S, Kanokmedhakul S, Tietjen I, Cherkasov A, Krajden M, Nabi IR, Niikura M, Shi P-Y, Andersen RJ, Jean F. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics [Internet]. Antiviral Research. 2023 ; 209 1-13.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.antiviral.2022.105484
Vancouver
Perez-Vargas J, Shapira T, Olmstead AD, Villanueva I, Thompson CAH, Ennis S, Gao G, Guzman JD, Williams DE, Wang M, Chin A, Bautista-Sanchez D, Agafitei O, Levett P, Xie X, Nuzzo G, Freire VF, Bulla JLQ, Bernardi DI, Gubiani JR, Suthiphasilp V, Raksat A, Meesakul P, Polbuppha I, Cheenpracha S, Jaidee W, Kanokmedhakul K, Yenjai C, Chaiyosang B, Teles HL, Manzo E, Fontana A, Leduc R, Boudreault P-L, Berlinck RG de S, Laphookhieo S, Kanokmedhakul S, Tietjen I, Cherkasov A, Krajden M, Nabi IR, Niikura M, Shi P-Y, Andersen RJ, Jean F. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics [Internet]. Antiviral Research. 2023 ; 209 1-13.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.antiviral.2022.105484
Artigo de periodico
Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections (2023)
Reinke, Patrick Y. A ; Souza, Edmarcia Elisa de ; Günther, Sebastian ; Falke, Sven ; Lieske, Julia ; Ewert, Wiebke ; Loboda, Jure ; Herrmann, Alexander ; Mashhour, Aida Rahmani ; Karnicar, Katarina ; Usenik, Aleksandra ; Lindic, Natasa ; Sekirnik, Andreja; Botosso, Viviane Fongaro ; Santelli, Glaucia Maria Machado ; Kapronezai, Josana ; Araujo, Marcelo Valdemir de ; Pereira, Taiana Tainá Silva ; Souza Filho, Antonio Francisco de ; Tavares, Mariana Silva; Flórez-Álvarez, Lizdany ; Oliveira, Danielle Bruna Leal de ; Durigon, Edison Luiz ; Giaretta, Paula Roberta ; Heinemann, Marcos Bryan ; Hauser, Maurice; Seychell, Brandon ; Böhler, Hendrik; Rut, Wioletta ; Drag, Marcin ; Beck, Tobias ; Cox, Russell ; Chapman, Henry N. ; Betzel, Christian ; Brehm, Wolfgang ; Hinrichs, Winfried ; Ebert, Gregor ; Latham, Sharissa L. ; Guimarães, Ana Marcia de Sá ; Turk, Dusan ; Wrenger, Carsten ; Meents, Alke
Source: Communications Biology. Unidades: ICB, FMVZ
Subjects: COVID-19, INIBIDORES DE ENZIMAS, ENZIMAS PROTEOLÍTICAS, ANTIVIRAIS, INFECÇÕES POR CORONAVIRUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REINKE, Patrick Y. A et al. Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections. Communications Biology, v. 6, p. 1-13, 2023Tradução . . Disponível em: https://doi.org/10.1038/s42003-023-05317-9. Acesso em: 01 nov. 2024.
APA
Reinke, P. Y. A., Souza, E. E. de, Günther, S., Falke, S., Lieske, J., Ewert, W., et al. (2023). Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections. Communications Biology, 6, 1-13. doi:10.1038/s42003-023-05317-9
NLM
Reinke PYA, Souza EE de, Günther S, Falke S, Lieske J, Ewert W, Loboda J, Herrmann A, Mashhour AR, Karnicar K, Usenik A, Lindic N, Sekirnik A, Botosso VF, Santelli GMM, Kapronezai J, Araujo MV de, Pereira TTS, Souza Filho AF de, Tavares MS, Flórez-Álvarez L, Oliveira DBL de, Durigon EL, Giaretta PR, Heinemann MB, Hauser M, Seychell B, Böhler H, Rut W, Drag M, Beck T, Cox R, Chapman HN, Betzel C, Brehm W, Hinrichs W, Ebert G, Latham SL, Guimarães AM de S, Turk D, Wrenger C, Meents A. Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections [Internet]. Communications Biology. 2023 ; 6 1-13.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s42003-023-05317-9
Vancouver
Reinke PYA, Souza EE de, Günther S, Falke S, Lieske J, Ewert W, Loboda J, Herrmann A, Mashhour AR, Karnicar K, Usenik A, Lindic N, Sekirnik A, Botosso VF, Santelli GMM, Kapronezai J, Araujo MV de, Pereira TTS, Souza Filho AF de, Tavares MS, Flórez-Álvarez L, Oliveira DBL de, Durigon EL, Giaretta PR, Heinemann MB, Hauser M, Seychell B, Böhler H, Rut W, Drag M, Beck T, Cox R, Chapman HN, Betzel C, Brehm W, Hinrichs W, Ebert G, Latham SL, Guimarães AM de S, Turk D, Wrenger C, Meents A. Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections [Internet]. Communications Biology. 2023 ; 6 1-13.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s42003-023-05317-9
Artigo de periodico
Some new insights into the biological activities of carboxymethylated polysaccharides from Lasiodiplodia theobromae (2023)
Pires, Matheus Cerdeira ; Andriolo, Natalia de Gois ; Lopes, Bruno Rafael Pereira; Ruiz, Ana Lucia Tasca Gois; Nascimento, Valeria Marta Gomes do; Toledo, Karina Alves; Santos, Catarina dos
Source: BMC Complementary Medicine and Therapies. Unidade: ESALQ
Subjects: ADJUVANTES IMUNOLÓGICOS, ANTICOAGULANTES, ANTIVIRAIS, BIOQUÍMICA MICROBIANA, FUNGOS, POLISSACARÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PIRES, Matheus Cerdeira et al. Some new insights into the biological activities of carboxymethylated polysaccharides from Lasiodiplodia theobromae. BMC Complementary Medicine and Therapies, v. 23, p. 1-11, 2023Tradução . . Disponível em: https://doi.org/10.1186/s12906-023-04190-7. Acesso em: 01 nov. 2024.
APA
Pires, M. C., Andriolo, N. de G., Lopes, B. R. P., Ruiz, A. L. T. G., Nascimento, V. M. G. do, Toledo, K. A., & Santos, C. dos. (2023). Some new insights into the biological activities of carboxymethylated polysaccharides from Lasiodiplodia theobromae. BMC Complementary Medicine and Therapies, 23, 1-11. doi:10.1186/s12906-023-04190-7
NLM
Pires MC, Andriolo N de G, Lopes BRP, Ruiz ALTG, Nascimento VMG do, Toledo KA, Santos C dos. Some new insights into the biological activities of carboxymethylated polysaccharides from Lasiodiplodia theobromae [Internet]. BMC Complementary Medicine and Therapies. 2023 ; 23 1-11.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1186/s12906-023-04190-7
Vancouver
Pires MC, Andriolo N de G, Lopes BRP, Ruiz ALTG, Nascimento VMG do, Toledo KA, Santos C dos. Some new insights into the biological activities of carboxymethylated polysaccharides from Lasiodiplodia theobromae [Internet]. BMC Complementary Medicine and Therapies. 2023 ; 23 1-11.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1186/s12906-023-04190-7
Artigo de periodico
Discovery of new Zika protease and polymerase inhibitors through the open science collaboration Project OpenZika (2022)
Mottin, Melina ; Sousa, Bruna Katiele de Paula ; Mesquita, Nathalya Cristina de Moraes Roso; Oliveira, Ketllyn Irene Zagato de; Noske, Gabriela Dias; Sartori, Geraldo Rodrigues ; Albuquerque, Aline de Oliveira; Urbina, Fabio; Puhl, Ana C. ; Moreira Filho, José Teófilo; Souza, Guilherme Eduardo de ; Guido, Rafael Victorio Carvalho ; Muratov, Eugene ; Neves, Bruno Junior ; Silva, João Hermínio Martins da ; Clark, Alex E.; Siqueira Neto, Jair L. ; Perryman, Alexander L.; Oliva, Glaucius ; Ekins, Sean ; Andrade, Carolina Horta
Source: Journal of Chemical Information and Modeling. Unidade: IFSC
Subjects: ZIKA VÍRUS, PLANEJAMENTO DE FÁRMACOS, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOTTIN, Melina et al. Discovery of new Zika protease and polymerase inhibitors through the open science collaboration Project OpenZika. Journal of Chemical Information and Modeling, v. 62, n. 24, p. 6825-6843, 2022Tradução . . Disponível em: https://doi.org/10.1021/acs.jcim.2c00596. Acesso em: 01 nov. 2024.
APA
Mottin, M., Sousa, B. K. de P., Mesquita, N. C. de M. R., Oliveira, K. I. Z. de, Noske, G. D., Sartori, G. R., et al. (2022). Discovery of new Zika protease and polymerase inhibitors through the open science collaboration Project OpenZika. Journal of Chemical Information and Modeling, 62( 24), 6825-6843. doi:10.1021/acs.jcim.2c00596
NLM
Mottin M, Sousa BK de P, Mesquita NC de MR, Oliveira KIZ de, Noske GD, Sartori GR, Albuquerque A de O, Urbina F, Puhl AC, Moreira Filho JT, Souza GE de, Guido RVC, Muratov E, Neves BJ, Silva JHM da, Clark AE, Siqueira Neto JL, Perryman AL, Oliva G, Ekins S, Andrade CH. Discovery of new Zika protease and polymerase inhibitors through the open science collaboration Project OpenZika [Internet]. Journal of Chemical Information and Modeling. 2022 ; 62( 24): 6825-6843.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1021/acs.jcim.2c00596
Vancouver
Mottin M, Sousa BK de P, Mesquita NC de MR, Oliveira KIZ de, Noske GD, Sartori GR, Albuquerque A de O, Urbina F, Puhl AC, Moreira Filho JT, Souza GE de, Guido RVC, Muratov E, Neves BJ, Silva JHM da, Clark AE, Siqueira Neto JL, Perryman AL, Oliva G, Ekins S, Andrade CH. Discovery of new Zika protease and polymerase inhibitors through the open science collaboration Project OpenZika [Internet]. Journal of Chemical Information and Modeling. 2022 ; 62( 24): 6825-6843.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1021/acs.jcim.2c00596
Artigo de periodico
Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems (2022)
Pinheiro, Lucas Barboza Moreira; Tao, Songsheng; Culbertson, Elizabeth; Araujo, Gabriel Lima Barros de ; Billinge, Simon J. L; Ferreira, Fabio Furlan
Source: International Journal of Pharmaceutics. Unidade: FCF
Subjects: CORONAVIRUS, ANTIVIRAIS, DIFRAÇÃO POR RAIOS X, ANTIRRETROVIRAIS, PLANEJAMENTO DE FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PINHEIRO, Lucas Barboza Moreira et al. Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems. International Journal of Pharmaceutics, v. 628, p. 1-9 art. 122329, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ijpharm.2022.122329. Acesso em: 01 nov. 2024.
APA
Pinheiro, L. B. M., Tao, S., Culbertson, E., Araujo, G. L. B. de, Billinge, S. J. L., & Ferreira, F. F. (2022). Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems. International Journal of Pharmaceutics, 628, 1-9 art. 122329. doi:10.1016/j.ijpharm.2022.122329
NLM
Pinheiro LBM, Tao S, Culbertson E, Araujo GLB de, Billinge SJL, Ferreira FF. Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems [Internet]. International Journal of Pharmaceutics. 2022 ; 628 1-9 art. 122329.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.ijpharm.2022.122329
Vancouver
Pinheiro LBM, Tao S, Culbertson E, Araujo GLB de, Billinge SJL, Ferreira FF. Evaluation of the polymorphic forms of ritonavir and lopinavir in raw materials and co-milled systems [Internet]. International Journal of Pharmaceutics. 2022 ; 628 1-9 art. 122329.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.ijpharm.2022.122329
Artigo de periodico
Vandetanib reduces inflammatory cytokines and ameliorates COVID-19 in infected mice (2021)
Puhl, Ana C.; Gomes, Giovanni Freitas; Damasceno, Samara; Fritch, Ethan J.; Levi, James A.; Johnson, Nicole J.; Scholle, Frank; Premkumar, Lakshmanane; Hurst, Brett L.; LeeMontiel, Felipe; Veras, Flávio Protásio; Batah, Sabrina Setembre ; Fabro, Alexandre Todorovic; Moorman, Nathaniel J.; Yount, Boyd L.; Dickmander, Rebekah; Baric, Ralph; Pearce, Kenneth H.; Cunha, Fernando de Queiroz ; Alves Filho, José Carlos Farias; Cunha, Thiago Mattar; Ekins, Sean
Source: bioRxiv. Unidades: FCFRP, FMRP
Subjects: ANTIVIRAIS, ANTINEOPLÁSICOS, CITOCINAS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PUHL, Ana C. et al. Vandetanib reduces inflammatory cytokines and ameliorates COVID-19 in infected mice. bioRxiv, p. 1-52, 2021Tradução . . Disponível em: https://doi.org/10.1101/2021.12.16.472155. Acesso em: 01 nov. 2024.
APA
Puhl, A. C., Gomes, G. F., Damasceno, S., Fritch, E. J., Levi, J. A., Johnson, N. J., et al. (2021). Vandetanib reduces inflammatory cytokines and ameliorates COVID-19 in infected mice. bioRxiv, 1-52. doi:10.1101/2021.12.16.472155
NLM
Puhl AC, Gomes GF, Damasceno S, Fritch EJ, Levi JA, Johnson NJ, Scholle F, Premkumar L, Hurst BL, LeeMontiel F, Veras FP, Batah SS, Fabro AT, Moorman NJ, Yount BL, Dickmander R, Baric R, Pearce KH, Cunha F de Q, Alves Filho JCF, Cunha TM, Ekins S. Vandetanib reduces inflammatory cytokines and ameliorates COVID-19 in infected mice [Internet]. bioRxiv. 2021 ; 1-52.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1101/2021.12.16.472155
Vancouver
Puhl AC, Gomes GF, Damasceno S, Fritch EJ, Levi JA, Johnson NJ, Scholle F, Premkumar L, Hurst BL, LeeMontiel F, Veras FP, Batah SS, Fabro AT, Moorman NJ, Yount BL, Dickmander R, Baric R, Pearce KH, Cunha F de Q, Alves Filho JCF, Cunha TM, Ekins S. Vandetanib reduces inflammatory cytokines and ameliorates COVID-19 in infected mice [Internet]. bioRxiv. 2021 ; 1-52.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1101/2021.12.16.472155
Artigo de periodico
Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus (2021)
Oliveira, Victor Gawriljuk Ferraro; Foil, Daniel H.; Puhl, Ana C. ; Zorn, Kimberley M.; Lane, Thomas R.; Riabova, Olga; Makarov, Vadim; Godoy, Andre Schutzer de ; Oliva, Glaucius ; Ekins, Sean
Source: Journal of Chemical Information and Modeling. Unidade: IFSC
Subjects: FEBRE AMARELA, APRENDIZADO COMPUTACIONAL, PLANEJAMENTO DE FÁRMACOS, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Victor Gawriljuk Ferraro et al. Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus. Journal of Chemical Information and Modeling, v. 61, n. 8, p. 3804-3813, 2021Tradução . . Disponível em: https://doi.org/10.1021/acs.jcim.1c00460. Acesso em: 01 nov. 2024.
APA
Oliveira, V. G. F., Foil, D. H., Puhl, A. C., Zorn, K. M., Lane, T. R., Riabova, O., et al. (2021). Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus. Journal of Chemical Information and Modeling, 61( 8), 3804-3813. doi:10.1021/acs.jcim.1c00460
NLM
Oliveira VGF, Foil DH, Puhl AC, Zorn KM, Lane TR, Riabova O, Makarov V, Godoy AS de, Oliva G, Ekins S. Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus [Internet]. Journal of Chemical Information and Modeling. 2021 ; 61( 8): 3804-3813.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1021/acs.jcim.1c00460
Vancouver
Oliveira VGF, Foil DH, Puhl AC, Zorn KM, Lane TR, Riabova O, Makarov V, Godoy AS de, Oliva G, Ekins S. Development of machine learning models and the discovery of a new antiviral compound against yellow fever virus [Internet]. Journal of Chemical Information and Modeling. 2021 ; 61( 8): 3804-3813.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1021/acs.jcim.1c00460
Artigo de periodico
Machine learning models identify inhibitors of SARS-CoV2 (2021)
Oliveira, Victor Gawriljuk Ferraro; Zin, Phyo Phyo Kyaw; Puhl, Ana C. ; Zorn, Kimberley M.; Foil, Daniel H.; Lane, Thomas R.; Hurst, Brett; Tavella, Tatyana Almeida; Costa, Fabio Trindade Maranhão; Lakshmanane, Premkumar; Bernatchez, Jean; Godoy, Andre Schutzer de ; Oliva, Glaucius ; Siqueira-Neto, Jair L.; Madrid, Peter B.; Ekins, Sean
Source: Journal of Chemical Information and Modeling. Unidade: IFSC
Subjects: CORONAVIRUS, COVID-19, APRENDIZADO COMPUTACIONAL, PLANEJAMENTO DE FÁRMACOS, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Victor Gawriljuk Ferraro et al. Machine learning models identify inhibitors of SARS-CoV2. Journal of Chemical Information and Modeling, v. 61, n. 9, p. 4224-4235, 2021Tradução . . Disponível em: https://doi.org/10.1021/acs.jcim.1c00683. Acesso em: 01 nov. 2024.
APA
Oliveira, V. G. F., Zin, P. P. K., Puhl, A. C., Zorn, K. M., Foil, D. H., Lane, T. R., et al. (2021). Machine learning models identify inhibitors of SARS-CoV2. Journal of Chemical Information and Modeling, 61( 9), 4224-4235. doi:10.1021/acs.jcim.1c00683
NLM
Oliveira VGF, Zin PPK, Puhl AC, Zorn KM, Foil DH, Lane TR, Hurst B, Tavella TA, Costa FTM, Lakshmanane P, Bernatchez J, Godoy AS de, Oliva G, Siqueira-Neto JL, Madrid PB, Ekins S. Machine learning models identify inhibitors of SARS-CoV2 [Internet]. Journal of Chemical Information and Modeling. 2021 ; 61( 9): 4224-4235.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1021/acs.jcim.1c00683
Vancouver
Oliveira VGF, Zin PPK, Puhl AC, Zorn KM, Foil DH, Lane TR, Hurst B, Tavella TA, Costa FTM, Lakshmanane P, Bernatchez J, Godoy AS de, Oliva G, Siqueira-Neto JL, Madrid PB, Ekins S. Machine learning models identify inhibitors of SARS-CoV2 [Internet]. Journal of Chemical Information and Modeling. 2021 ; 61( 9): 4224-4235.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1021/acs.jcim.1c00683
Artigo de periodico
Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events (2021)
Voges, Alessandra Rinah Nogueira; Ubukata, Rodrigo; Yazbek, Karina Velloso Braga; Caballero, Otávia Luisa; Salazar, Andres Mario; Massoco, Cristina de Oliveira ; Dagli, Maria Lúcia Zaidan
Source: Cancers. Unidade: FMVZ
Subjects: CÃES, ANTIVIRAIS, IMUNOTERAPIA, NEOPLASIAS EM ANIMAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VOGES, Alessandra Rinah Nogueira et al. Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events. Cancers, v. 13, n. 9, p. 1-11, 2021Tradução . . Disponível em: https://doi.org/10.3390/cancers13092237. Acesso em: 01 nov. 2024.
APA
Voges, A. R. N., Ubukata, R., Yazbek, K. V. B., Caballero, O. L., Salazar, A. M., Massoco, C. de O., & Dagli, M. L. Z. (2021). Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events. Cancers, 13( 9), 1-11. doi:10.3390/cancers13092237
NLM
Voges ARN, Ubukata R, Yazbek KVB, Caballero OL, Salazar AM, Massoco C de O, Dagli MLZ. Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events [Internet]. Cancers. 2021 ; 13( 9): 1-11.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3390/cancers13092237
Vancouver
Voges ARN, Ubukata R, Yazbek KVB, Caballero OL, Salazar AM, Massoco C de O, Dagli MLZ. Intratumoral (Poly-ICLC) therapy for dogs with advanced cancers: first report on clinical effectiveness, quality of life, and adverse events [Internet]. Cancers. 2021 ; 13( 9): 1-11.[citado 2024 nov. 01 ] Available from: https://doi.org/10.3390/cancers13092237
Artigo de periodico
AHR is a Zika virus host factor and a candidate target for antiviral therapy (2020)
Giovannoni, Federico ; Bosch, Irene ; Polonio, Carolina Manganeli ; Torti, María F.; Wheeler, Michael A.; Li, Zhaorong ; Romorini, Leonardo ; Varela, María S. Rodriguez; Rothhammer, Veit ; Barroso, Andreia ; Tjon, Emily C.; Sanmarco, Liliana M.; Takenaka, Maisa C.; Modaresi, Seyed Mohamad Sadegh ; Vázquez, Cristina Gutiérrez; Zanluqui, Nágela Ghabdan ; Santos, Nilton Barreto dos ; Munhoz, Carolina Demarchi ; Wang, Zhongyan; Damonte, Elsa B.; Sherr, David; Gehrke, Lee ; Peron, Jean Pierre Schatzmann ; Garcia, Cybele C. ; Quintana, Francisco J.
Source: Nature Neuroscience. Unidades: ICB, FM
Subjects: IMUNOLOGIA, FARMACOLOGIA, ZIKA VÍRUS, VÍRUS, FLAVIVIRUS, MICROCEFALIA, TRANSCRIÇÃO GÊNICA, GENOMAS, HIDROCARBONETOS, INTERFERON TIPO I, ANTIVIRAIS, REPLICAÇÃO VIRAL, NANOPARTÍCULAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIOVANNONI, Federico et al. AHR is a Zika virus host factor and a candidate target for antiviral therapy. Nature Neuroscience, v. 23, p. 939–951, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41593-020-0664-0. Acesso em: 01 nov. 2024.
APA
Giovannoni, F., Bosch, I., Polonio, C. M., Torti, M. F., Wheeler, M. A., Li, Z., et al. (2020). AHR is a Zika virus host factor and a candidate target for antiviral therapy. Nature Neuroscience, 23, 939–951. doi:10.1038/s41593-020-0664-0
NLM
Giovannoni F, Bosch I, Polonio CM, Torti MF, Wheeler MA, Li Z, Romorini L, Varela MSR, Rothhammer V, Barroso A, Tjon EC, Sanmarco LM, Takenaka MC, Modaresi SMS, Vázquez CG, Zanluqui NG, Santos NB dos, Munhoz CD, Wang Z, Damonte EB, Sherr D, Gehrke L, Peron JPS, Garcia CC, Quintana FJ. AHR is a Zika virus host factor and a candidate target for antiviral therapy [Internet]. Nature Neuroscience. 2020 ; 23 939–951.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41593-020-0664-0
Vancouver
Giovannoni F, Bosch I, Polonio CM, Torti MF, Wheeler MA, Li Z, Romorini L, Varela MSR, Rothhammer V, Barroso A, Tjon EC, Sanmarco LM, Takenaka MC, Modaresi SMS, Vázquez CG, Zanluqui NG, Santos NB dos, Munhoz CD, Wang Z, Damonte EB, Sherr D, Gehrke L, Peron JPS, Garcia CC, Quintana FJ. AHR is a Zika virus host factor and a candidate target for antiviral therapy [Internet]. Nature Neuroscience. 2020 ; 23 939–951.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41593-020-0664-0
Artigo de periodico
COVID-19 Pandemic: a narrative review of the potential roles of chloroquine and hydroxychloroquine (2020)
Barros, Carlos M. de; Almeida, Carolina A. de Faria; Pereira, Bruna Pinheiro; Costa, Karla Cristinne Mancini ; Pinheiro, Flaviane A.; Maia, Livia Del Bianco; Trindade, Cristiano Morais da; Garcia, Raphael Caio Tamborelli; Torres, Larissa Helena; Diwan, Sudhir; Boralli, Vanessa Bergamin
Source: Pain Physician. Unidade: FMRP
Subjects: ANTIVIRAIS, COVID-19, INFECÇÕES POR CORONAVIRUS, PANDEMIAS, PNEUMONIA, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARROS, Carlos M. de et al. COVID-19 Pandemic: a narrative review of the potential roles of chloroquine and hydroxychloroquine. Pain Physician, v. 23, p. S351-S366, 2020Tradução . . Disponível em: https://www.painphysicianjournal.com/current/pdf?article=NzEwNg%3D%3D&journal=129. Acesso em: 01 nov. 2024.
APA
Barros, C. M. de, Almeida, C. A. de F., Pereira, B. P., Costa, K. C. M., Pinheiro, F. A., Maia, L. D. B., et al. (2020). COVID-19 Pandemic: a narrative review of the potential roles of chloroquine and hydroxychloroquine. Pain Physician, 23, S351-S366. Recuperado de https://www.painphysicianjournal.com/current/pdf?article=NzEwNg%3D%3D&journal=129
NLM
Barros CM de, Almeida CA de F, Pereira BP, Costa KCM, Pinheiro FA, Maia LDB, Trindade CM da, Garcia RCT, Torres LH, Diwan S, Boralli VB. COVID-19 Pandemic: a narrative review of the potential roles of chloroquine and hydroxychloroquine [Internet]. Pain Physician. 2020 ; 23 S351-S366.[citado 2024 nov. 01 ] Available from: https://www.painphysicianjournal.com/current/pdf?article=NzEwNg%3D%3D&journal=129
Vancouver
Barros CM de, Almeida CA de F, Pereira BP, Costa KCM, Pinheiro FA, Maia LDB, Trindade CM da, Garcia RCT, Torres LH, Diwan S, Boralli VB. COVID-19 Pandemic: a narrative review of the potential roles of chloroquine and hydroxychloroquine [Internet]. Pain Physician. 2020 ; 23 S351-S366.[citado 2024 nov. 01 ] Available from: https://www.painphysicianjournal.com/current/pdf?article=NzEwNg%3D%3D&journal=129
Artigo de periodico
The global response to the COVID-19 pandemic: how have immunology societies contributed ? (2020)
Osier, Faith; Ting, Jenny P. Y.; Fraser, John; Lambrecht, Bart N.; Romano, Marta; Gazzinelli, Ricardo Tostes ; Bortoluci, Karina Ramalho ; Zamboni, Dario Simões ; Akbar, Arne N.; Evans, Jennie; Brown, Doug E.; Patel, Kamala D.; Wu, Yuzhang; Perez, Ana Beatriz Alvarez; Pérez, Oliver; Kamradt, Thomas; Falk, Christine; Barda-Saad, Mira; Ariel, Amiram; Santoni, Angela; Annunziato, Francesco; Cassatella, Marco A.; Kiyono, Hiroshi; Chereshnev, Valeriy; Dieye, Alioune; Mbow, Moustapha; Mbengue, Babacar; Niang, Maguette D. S.; Suchard, Melinda
Source: Nature Reviews Immunology. Unidade: FMRP
Subjects: ANTIVIRAIS, USOS TERAPÊUTICOS, IMUNOLOGIA, COVID-19, INFECÇÕES POR CORONAVIRUS, PREVENÇÃO DE DOENÇAS, EPIDEMIOLOGIA, VACINAS, EDUCAÇÃO DO PACIENTE, EQUIPAMENTO DE PROTEÇÃO INDIVIDUAL, PNEUMONIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OSIER, Faith et al. The global response to the COVID-19 pandemic: how have immunology societies contributed ?. Nature Reviews Immunology, v. 20, p. 594-602, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41577-020-00428-4. Acesso em: 01 nov. 2024.
APA
Osier, F., Ting, J. P. Y., Fraser, J., Lambrecht, B. N., Romano, M., Gazzinelli, R. T., et al. (2020). The global response to the COVID-19 pandemic: how have immunology societies contributed ? Nature Reviews Immunology, 20, 594-602. doi:10.1038/s41577-020-00428-4
NLM
Osier F, Ting JPY, Fraser J, Lambrecht BN, Romano M, Gazzinelli RT, Bortoluci KR, Zamboni DS, Akbar AN, Evans J, Brown DE, Patel KD, Wu Y, Perez ABA, Pérez O, Kamradt T, Falk C, Barda-Saad M, Ariel A, Santoni A, Annunziato F, Cassatella MA, Kiyono H, Chereshnev V, Dieye A, Mbow M, Mbengue B, Niang MDS, Suchard M. The global response to the COVID-19 pandemic: how have immunology societies contributed ? [Internet]. Nature Reviews Immunology. 2020 ; 20 594-602.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41577-020-00428-4
Vancouver
Osier F, Ting JPY, Fraser J, Lambrecht BN, Romano M, Gazzinelli RT, Bortoluci KR, Zamboni DS, Akbar AN, Evans J, Brown DE, Patel KD, Wu Y, Perez ABA, Pérez O, Kamradt T, Falk C, Barda-Saad M, Ariel A, Santoni A, Annunziato F, Cassatella MA, Kiyono H, Chereshnev V, Dieye A, Mbow M, Mbengue B, Niang MDS, Suchard M. The global response to the COVID-19 pandemic: how have immunology societies contributed ? [Internet]. Nature Reviews Immunology. 2020 ; 20 594-602.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41577-020-00428-4
Artigo de periodico
(±)-Licarin A and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities (2020)
Meleti, Vanderlisa Rita; Esperandim, Viviane Rodrigues; Flauzino, Luzio Gabriel Bocalon; Prizantelli, Anna Helena; Paula, Lucas Antônio de Lima; Magalhães, Lizandra Guidi; Cunha, Wilson Roberto; Laurentiz, Rosângela da Silva; Pissurno, Ana Paula da Rocha; Nanayakkara, N. P. Dhammika; Pereira, Ana Carolina; Bastos, Jairo Kenupp ; Parreira, Renato Luis Tâme; Orenha, Renato Pereira; Silva, Márcio Luis Andrade e
Source: Acta Tropica. Unidade: FCFRP
Subjects: TRYPANOSOMA CRUZI, SCHISTOSOMA MANSONI, ANTIVIRAIS, ANTIFÚNGICOS, COMPOSTOS ORGÂNICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MELETI, Vanderlisa Rita et al. (±)-Licarin A and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities. Acta Tropica, v. 202, p. 1-8, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.actatropica.2019.105248. Acesso em: 01 nov. 2024.
APA
Meleti, V. R., Esperandim, V. R., Flauzino, L. G. B., Prizantelli, A. H., Paula, L. A. de L., Magalhães, L. G., et al. (2020). (±)-Licarin A and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities. Acta Tropica, 202, 1-8. doi:10.1016/j.actatropica.2019.105248
NLM
Meleti VR, Esperandim VR, Flauzino LGB, Prizantelli AH, Paula LA de L, Magalhães LG, Cunha WR, Laurentiz R da S, Pissurno AP da R, Nanayakkara NPD, Pereira AC, Bastos JK, Parreira RLT, Orenha RP, Silva MLA e. (±)-Licarin A and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities [Internet]. Acta Tropica. 2020 ; 202 1-8.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.actatropica.2019.105248
Vancouver
Meleti VR, Esperandim VR, Flauzino LGB, Prizantelli AH, Paula LA de L, Magalhães LG, Cunha WR, Laurentiz R da S, Pissurno AP da R, Nanayakkara NPD, Pereira AC, Bastos JK, Parreira RLT, Orenha RP, Silva MLA e. (±)-Licarin A and its semi-synthetic derivatives: in vitro and in silico evaluation of trypanocidal and schistosomicidal activities [Internet]. Acta Tropica. 2020 ; 202 1-8.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.actatropica.2019.105248
Artigo de periodico
A diarylamine derived from anthranilic acid inhibits ZIKV replication (2019)
Silva, Suely; Shimizu, Jacqueline Farinha; Oliveira, Débora Moraes de; Assis, Leticia Ribeiro de; Bittar, Cintia; Mottin, Melina; Sousa, Bruna Katiele de Paula; Mesquita, Nathalya Cristina de Moraes Roso; Regasini, Luis Octávio; Rahal, Paula; Oliva, Glaucius ; Perryman, Alexander Luke; Ekins, Sean; Andrade, Carolina Horta; Goulart, Luiz Ricardo; Sabino-Silva, Robinson; Merits, Andres; Harris, Mark; Jardim, Ana Carolina Gomes
Source: Scientific Reports. Unidade: IFSC
Subjects: ANTIVIRAIS, ZIKA VÍRUS, FLAVIVIRUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Suely et al. A diarylamine derived from anthranilic acid inhibits ZIKV replication. Scientific Reports, v. 9, p. 17703-1-17703-12, 2019Tradução . . Disponível em: https://doi.org/10.1038/s41598-019-54169-z. Acesso em: 01 nov. 2024.
APA
Silva, S., Shimizu, J. F., Oliveira, D. M. de, Assis, L. R. de, Bittar, C., Mottin, M., et al. (2019). A diarylamine derived from anthranilic acid inhibits ZIKV replication. Scientific Reports, 9, 17703-1-17703-12. doi:10.1038/s41598-019-54169-z
NLM
Silva S, Shimizu JF, Oliveira DM de, Assis LR de, Bittar C, Mottin M, Sousa BK de P, Mesquita NC de MR, Regasini LO, Rahal P, Oliva G, Perryman AL, Ekins S, Andrade CH, Goulart LR, Sabino-Silva R, Merits A, Harris M, Jardim ACG. A diarylamine derived from anthranilic acid inhibits ZIKV replication [Internet]. Scientific Reports. 2019 ; 9 17703-1-17703-12.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41598-019-54169-z
Vancouver
Silva S, Shimizu JF, Oliveira DM de, Assis LR de, Bittar C, Mottin M, Sousa BK de P, Mesquita NC de MR, Regasini LO, Rahal P, Oliva G, Perryman AL, Ekins S, Andrade CH, Goulart LR, Sabino-Silva R, Merits A, Harris M, Jardim ACG. A diarylamine derived from anthranilic acid inhibits ZIKV replication [Internet]. Scientific Reports. 2019 ; 9 17703-1-17703-12.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1038/s41598-019-54169-z
Trabalho de evento-resumo
Discovery of flavonoids from Pterogyne nitens with potent activity against Zika virus protease and helicase (2019)
Mottin, Melina; Lima, Caroline S.; Mesquita, Nathalya Cristina de Moraes Roso; Zorn, Kimberley M.; Ekins, Sean; Oliva, Glaucius ; Regasini, Luís O.; Andrade, Carolina Horta
Source: Anais eletrônicos. Conference titles: Brazilian Symposium on Medicinal Chemistry - BrazMedChem. Unidade: IFSC
Subjects: ZIKA VÍRUS, PRODUTOS NATURAIS, ENZIMAS, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOTTIN, Melina et al. Discovery of flavonoids from Pterogyne nitens with potent activity against Zika virus protease and helicase. 2019, Anais.. Campinas: Galoá, 2019. Disponível em: https://proceedings.science/p/107236. Acesso em: 01 nov. 2024.
APA
Mottin, M., Lima, C. S., Mesquita, N. C. de M. R., Zorn, K. M., Ekins, S., Oliva, G., et al. (2019). Discovery of flavonoids from Pterogyne nitens with potent activity against Zika virus protease and helicase. In Anais eletrônicos. Campinas: Galoá. Recuperado de https://proceedings.science/p/107236
NLM
Mottin M, Lima CS, Mesquita NC de MR, Zorn KM, Ekins S, Oliva G, Regasini LO, Andrade CH. Discovery of flavonoids from Pterogyne nitens with potent activity against Zika virus protease and helicase [Internet]. Anais eletrônicos. 2019 ;[citado 2024 nov. 01 ] Available from: https://proceedings.science/p/107236
Vancouver
Mottin M, Lima CS, Mesquita NC de MR, Zorn KM, Ekins S, Oliva G, Regasini LO, Andrade CH. Discovery of flavonoids from Pterogyne nitens with potent activity against Zika virus protease and helicase [Internet]. Anais eletrônicos. 2019 ;[citado 2024 nov. 01 ] Available from: https://proceedings.science/p/107236
Artigo de periodico
Modeling neuro-immune interactions during Zika virus infection (2018)
Mesci, Pinar; Macia, Angela; LaRock, Christopher N.; Tejwani, Leon; Fernandes, Isabella R.; Nicole A.; Zanotto, Paolo Marinho de Andrade ; Beltrão-Braga, Patrícia ; Nizet, Victor; Muotri, Alysson R.
Source: Human Molecular Genetics. Unidades: EACH, ICB
Subjects: ZIKA VÍRUS, MICROBIOLOGIA, NEONATOLOGIA, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MESCI, Pinar et al. Modeling neuro-immune interactions during Zika virus infection. Human Molecular Genetics, v. 27, n. Ja 2018, p. 41-52, 2018Tradução . . Disponível em: https://doi.org/10.1093/hmg/ddx382. Acesso em: 01 nov. 2024.
APA
Mesci, P., Macia, A., LaRock, C. N., Tejwani, L., Fernandes, I. R., Nicole A.,, et al. (2018). Modeling neuro-immune interactions during Zika virus infection. Human Molecular Genetics, 27( Ja 2018), 41-52. doi:10.1093/hmg/ddx382
NLM
Mesci P, Macia A, LaRock CN, Tejwani L, Fernandes IR, Nicole A., Zanotto PM de A, Beltrão-Braga P, Nizet V, Muotri AR. Modeling neuro-immune interactions during Zika virus infection [Internet]. Human Molecular Genetics. 2018 ; 27( Ja 2018): 41-52.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1093/hmg/ddx382
Vancouver
Mesci P, Macia A, LaRock CN, Tejwani L, Fernandes IR, Nicole A., Zanotto PM de A, Beltrão-Braga P, Nizet V, Muotri AR. Modeling neuro-immune interactions during Zika virus infection [Internet]. Human Molecular Genetics. 2018 ; 27( Ja 2018): 41-52.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1093/hmg/ddx382
Trabalho de evento-resumo
OpenZika: discovery of new antiviral candidates against Zika virus (2018)
Mottin, Melina; Carvalho, Amanda S.; Melo-Filho, Cleber C.; Neves, Bruno J.; Braga, Rodolpho C.; Lima, Caroline S.; Silva, Suely da; Shimizu, Jacqueline F.; Mesquita, Nathalya C. M. R.; Regasini, Luis O.; Jardim, Ana C.; Muratov, Eugene; Oliva, Glaucius ; Perryman, Alexander L.; Ekins, Sean; Andrade, Carolina Horta
Source: Abstracts. Conference titles: ACS National Meeting and Exposition. Unidade: IFSC
Subjects: ANTIVIRAIS, ZIKA VÍRUS, FLAVIVIRUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOTTIN, Melina et al. OpenZika: discovery of new antiviral candidates against Zika virus. 2018, Anais.. Washington, DC: American Chemical Society - ACS, 2018. Disponível em: https://plan.core-apps.com/acsboston18/abstract/21fce65b-dede-4f12-92b8-c6700f6cc235. Acesso em: 01 nov. 2024.
APA
Mottin, M., Carvalho, A. S., Melo-Filho, C. C., Neves, B. J., Braga, R. C., Lima, C. S., et al. (2018). OpenZika: discovery of new antiviral candidates against Zika virus. In Abstracts. Washington, DC: American Chemical Society - ACS. Recuperado de https://plan.core-apps.com/acsboston18/abstract/21fce65b-dede-4f12-92b8-c6700f6cc235
NLM
Mottin M, Carvalho AS, Melo-Filho CC, Neves BJ, Braga RC, Lima CS, Silva S da, Shimizu JF, Mesquita NCMR, Regasini LO, Jardim AC, Muratov E, Oliva G, Perryman AL, Ekins S, Andrade CH. OpenZika: discovery of new antiviral candidates against Zika virus [Internet]. Abstracts. 2018 ;[citado 2024 nov. 01 ] Available from: https://plan.core-apps.com/acsboston18/abstract/21fce65b-dede-4f12-92b8-c6700f6cc235
Vancouver
Mottin M, Carvalho AS, Melo-Filho CC, Neves BJ, Braga RC, Lima CS, Silva S da, Shimizu JF, Mesquita NCMR, Regasini LO, Jardim AC, Muratov E, Oliva G, Perryman AL, Ekins S, Andrade CH. OpenZika: discovery of new antiviral candidates against Zika virus [Internet]. Abstracts. 2018 ;[citado 2024 nov. 01 ] Available from: https://plan.core-apps.com/acsboston18/abstract/21fce65b-dede-4f12-92b8-c6700f6cc235
Artigo de periodico
Polymorphs of the antiviral drug ganciclovir (2017)
Flores, Roxana L. Roque; Guzei, Ilia A; Matos, Jivaldo do Rosário ; Yu, Lian
Source: Acta Crystallographica Section C. Unidade: IQ
Subjects: POLIMORFISMO, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FLORES, Roxana L. Roque et al. Polymorphs of the antiviral drug ganciclovir. Acta Crystallographica Section C, v. 73, p. 1116-1120, 2017Tradução . . Disponível em: https://doi.org/10.1107/S2053229617016059. Acesso em: 01 nov. 2024.
APA
Flores, R. L. R., Guzei, I. A., Matos, J. do R., & Yu, L. (2017). Polymorphs of the antiviral drug ganciclovir. Acta Crystallographica Section C, 73, 1116-1120. doi:10.1107/S2053229617016059
NLM
Flores RLR, Guzei IA, Matos J do R, Yu L. Polymorphs of the antiviral drug ganciclovir [Internet]. Acta Crystallographica Section C. 2017 ; 73 1116-1120.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1107/S2053229617016059
Vancouver
Flores RLR, Guzei IA, Matos J do R, Yu L. Polymorphs of the antiviral drug ganciclovir [Internet]. Acta Crystallographica Section C. 2017 ; 73 1116-1120.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1107/S2053229617016059
Trabalho de evento-resumo periodico
Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis (2016)
Pessoa, Mario G.; Ramalho, José Valdez Madruga; Alves, Katia; Cohen, Daniel E.; Nunes, Estevao Portela; Cheinquer, Hugo; Brandão-Mello, Carlos E.; Mendes-Côrrea, Maria Cássia Jacintho; Ferraz, Maria Lucia G.; Lari, Sara; Lui, Li; Tripathi, Rakesh; Pilot-Matias, Tami; Schulman, Nancy; Martinelli, Ana de Lourdes Candolo
Source: Hepatology. Conference titles: Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Unidades: FMRP, FM
Subjects: HEPATITE C, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PESSOA, Mario G. et al. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis. Hepatology. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/hep.28800. Acesso em: 01 nov. 2024. , 2016
APA
Pessoa, M. G., Ramalho, J. V. M., Alves, K., Cohen, D. E., Nunes, E. P., Cheinquer, H., et al. (2016). Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis. Hepatology. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/hep.28800
NLM
Pessoa MG, Ramalho JVM, Alves K, Cohen DE, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Côrrea MCJ, Ferraz MLG, Lari S, Lui L, Tripathi R, Pilot-Matias T, Schulman N, Martinelli A de LC. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis [Internet]. Hepatology. 2016 ; 64 949A-950A.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1002/hep.28800
Vancouver
Pessoa MG, Ramalho JVM, Alves K, Cohen DE, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Côrrea MCJ, Ferraz MLG, Lari S, Lui L, Tripathi R, Pilot-Matias T, Schulman N, Martinelli A de LC. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis [Internet]. Hepatology. 2016 ; 64 949A-950A.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1002/hep.28800

USP Schools

ReP

Filtros

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Grupo de pesquisa

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration